220 related articles for article (PubMed ID: 9331107)
1. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue.
Hamdy FC; Autzen P; Robinson MC; Horne CH; Neal DE; Robson CN
Cancer Res; 1997 Oct; 57(19):4427-31. PubMed ID: 9331107
[TBL] [Abstract][Full Text] [Related]
2. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.
Masuda H; Fukabori Y; Nakano K; Takezawa Y; CSuzuki T; Yamanaka H
Prostate; 2003 Mar; 54(4):268-74. PubMed ID: 12539225
[TBL] [Abstract][Full Text] [Related]
4. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer.
Bobinac D; Marić I; Zoricić S; Spanjol J; Dordević G; Mustać E; Fuckar Z
Croat Med J; 2005 Jun; 46(3):389-96. PubMed ID: 15861517
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer.
Tamada H; Kitazawa R; Gohji K; Kitazawa S
J Bone Miner Res; 2001 Mar; 16(3):487-96. PubMed ID: 11277266
[TBL] [Abstract][Full Text] [Related]
6. Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study.
Spanjol J; Djordjević G; Markić D; Klarić M; Fuckar D; Bobinac D
Coll Antropol; 2010 Apr; 34 Suppl 2():119-25. PubMed ID: 21302710
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.
Autzen P; Robson CN; Bjartell A; Malcolm AJ; Johnson MI; Neal DE; Hamdy FC
Br J Cancer; 1998 Nov; 78(9):1219-23. PubMed ID: 9820184
[TBL] [Abstract][Full Text] [Related]
8. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate.
Masuda H; Fukabori Y; Nakano K; Shimizu N; Yamanaka H
Prostate; 2004 Apr; 59(1):101-6. PubMed ID: 14991870
[TBL] [Abstract][Full Text] [Related]
9. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
Haudenschild DR; Palmer SM; Moseley TA; You Z; Reddi AH
Cancer Res; 2004 Nov; 64(22):8276-84. PubMed ID: 15548695
[TBL] [Abstract][Full Text] [Related]
10. c-met proto-oncogene expression in benign and malignant human prostate tissues.
Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
[TBL] [Abstract][Full Text] [Related]
11. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
[TBL] [Abstract][Full Text] [Related]
15. Immunolocalization and mRNA expression of bone morphogenetic protein-6 in human clear cell renal carcinoma.
Basic-Jukic N; Radic-Antolic M; Hudolin T; Coric M; Zadro R; Pasini J; Kastelan Z; Kes P
Kidney Blood Press Res; 2009; 32(6):445-50. PubMed ID: 20016212
[TBL] [Abstract][Full Text] [Related]
16. Bone morphogenetic proteins are expressed by both bone-forming and non-bone-forming lesions.
Khurana JS; Ogino S; Shen T; Parekh H; Scherbel U; DeLong W; Feldman MD; Zhang PJ; Wolfe HJ; Alman BA
Arch Pathol Lab Med; 2004 Nov; 128(11):1267-69. PubMed ID: 15508192
[TBL] [Abstract][Full Text] [Related]
17. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
18. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
19. Expression of ezrin in prostatic intraepithelial neoplasia.
Pang ST; Fang X; Valdman A; Norstedt G; Pousette A; Egevad L; Ekman P
Urology; 2004 Mar; 63(3):609-12. PubMed ID: 15028477
[TBL] [Abstract][Full Text] [Related]
20. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
